Reversing factor Xa inhibitors – clinical utility of andexanet alfa

Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaatz, Scott, Bhansali, Hardik, Gibbs, Joseph, Lavender, Robert, Mahan, Charles E, Paje, David G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602457/
https://www.ncbi.nlm.nih.gov/pubmed/28979172
http://dx.doi.org/10.2147/JBM.S121550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602457/
https://www.ncbi.nlm.nih.gov/pubmed/28979172
http://dx.doi.org/10.2147/JBM.S121550

Ejemplares similares